New ultra-low dose pill 100% effective in lowering BP: Lancet

Image
IANS Sydney
Last Updated : Feb 10 2017 | 5:57 PM IST

A new ultra-low dose four-in-one pill that is 100 per cent effective in lowering high blood pressure has been developed by Australian researchers.

Hypertension or high blood pressure -- which affects around 1.1 billion people worldwide -- is one of the major risk factors for heart attack, stroke, dementia and kidney disease.

Researchers from the University of Sydney in Australia, prescribed a quadpill -- a single capsule containing four of the most commonly used blood pressure-lowering drugs each at a quarter dose (irbesartan 37·5 mg, amlodipine 1·25 mg, hydrochlorothiazide 6·25 mg, and atenolol 12·5 mg) -- or a placebo to 18 patients in Sydney over four weeks.

The results, published in The Lancet medical journal, revealed that 100 per cent of patients on trial saw their blood levels dropping below 140 over 90, whereas just 33 per cent of patients on the placebo could achieve this rate.

"Most people receive one medicine at a normal dose but that only controls blood pressure about half the time. In this small trial, blood pressure control was achieved for everyone," said Clara Chow, Professor at the University of Sydney in Australia.

Patients who consume the commonly available hypertension-lowering drugs experience side-effects which can vary from swollen ankles to kidney abnormalities depending on the type of class of the drug.

However, the new pill has no such side-effects, the researchers said.

"We know that high blood pressure is a precursor to stroke, diabetes and heart attack. The need for even lower blood pressure levels has been widely accepted in the last few years. So this could be an incredibly important step in helping to reduce the burden of disease globally," Chow added.

--IANS

rt/sm/dg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 10 2017 | 5:46 PM IST

Next Story